T. Rowe Price Associates
MNPR icon

T. Rowe Price Associates’s Monopar Therapeutics MNPR Stock Holding History

T. Rowe Price Associates’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.61M Buy
47,702
+24,975
+110% +$1.51M ﹤0.01% 1709
2025
Q4 		$1.49M Buy
+22,727
New +$1.86M ﹤0.01% 1899

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates's MNPR Position: Q1 2026 in Review

T. Rowe Price Associates increased its Monopar Therapeutics (MNPR) stake by 110% in Q1 2026, buying an estimated $1.51M and bringing the position to 47,702 shares worth $2.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

T. Rowe Price Associates first reported a position in MNPR in Q4 2025 and has held it in 2 quarters since. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • T. Rowe Price Associates held 47,702 shares of Monopar Therapeutics worth $2.61M as of Q1 2026.
  • T. Rowe Price Associates bought 24,975 Monopar Therapeutics shares in Q1 2026, an estimated $1.51M.
  • Monopar Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1709 holding.
  • T. Rowe Price Associates first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.